Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.
about
New perspectives on the role of vitiligo in immune responses to melanomaMonobenzone-induced depigmentation: from enzymatic blockade to autoimmunityAutoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanomaIntravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in miceTopical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatmentA DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model.Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model.Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.A mouse model of vitiligo induced by monobenzone.Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial.Inhibitory effects of 16-hydroxy-9-oxo-10E,12E,14E-octadecatrienoic acid (Corchorifatty acid B) isolated from Melissa officinalis Linné on melanogenesis.
P2860
Q26996799-53B201C4-90C8-4217-9C5A-F92B91835890Q28241227-183A11DF-2C90-4A6D-858B-3E6280BD7E70Q33829513-F46E837F-806C-4EE3-AC41-57FD282AF754Q34020057-4E53162F-2A69-4277-84EC-DBCD5659023EQ34876334-797A900E-9AC4-4DB5-9608-B6446E4721CEQ36612204-49ED486C-E06E-453D-8D4A-A3E93BD1F24EQ36871503-A268D6C7-9C53-4D65-973A-D6B56FC22CB4Q37530511-997AEF38-BD78-4E8D-A60D-1BFC5AD806FBQ38166382-AB057C47-4612-4026-B9AB-EE7024901EF6Q39127839-C60BD2E4-3E5E-40FD-B70B-A4AB6CC51554Q41205680-DD514D4D-E951-4AF6-8975-71243B28B8C0Q45920052-399A1DE9-69FE-422D-A67F-791FFB30E1E6Q52597538-8D622BFB-EC18-4501-B8FC-6719CD20372DQ53261058-1A9545F0-E49F-4C59-91B8-0DA6A6EF9423
P2860
Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effective melanoma immunothera ...... e adjuvants imiquimod and CpG.
@ast
Effective melanoma immunothera ...... e adjuvants imiquimod and CpG.
@en
Effective melanoma immunothera ...... e adjuvants imiquimod and CpG.
@nl
type
label
Effective melanoma immunothera ...... e adjuvants imiquimod and CpG.
@ast
Effective melanoma immunothera ...... e adjuvants imiquimod and CpG.
@en
Effective melanoma immunothera ...... e adjuvants imiquimod and CpG.
@nl
prefLabel
Effective melanoma immunothera ...... e adjuvants imiquimod and CpG.
@ast
Effective melanoma immunothera ...... e adjuvants imiquimod and CpG.
@en
Effective melanoma immunothera ...... e adjuvants imiquimod and CpG.
@nl
P2093
P2860
P1433
P1476
Effective melanoma immunothera ...... e adjuvants imiquimod and CpG.
@en
P2093
Cornelis J M Melief
Daisy I Picavet
Debby Konijnenberg
Dmitri V Filippov
Esther P M Tjin
J P Wietze van der Veen
Jasper G van den Boorn
Nico J Meeuwenoord
P2860
P304
P356
10.1371/JOURNAL.PONE.0010626
P407
P577
2010-05-13T00:00:00Z